

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is for information purposes only, and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Beijing Chunlizhengda Medical Instruments Co., Ltd.**



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

INSIDE INFORMATION 2023 PRELIMINARY RESULTS ANNOUNCEMENT

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Please also refer to the overseas regulatory announcement of the Company dated 28 February 2024.

The major financial data for the year 2023 contained in this announcement is preliminary accounting data, which has not been audited by an accounting firm and is subject to the 2023 annual report of the Company. Investors are advised to pay attention to investment risks.

I. KEY FINANCIAL DATA AND INDICATORS FOR THE YEAR 2023

Unit: RMB, Share

Item	Reporting period	Corresponding period of last year	Increase/decrease (%)
Total operating revenue	1,208,523,845.88	1,201,604,254.24	0.58
Operating profit	305,975,463.53	328,908,764.68	-6.97
Gross profit	305,905,863.04	336,879,766.43	-9.19
Net profit attributable to owners of the parent company	277,824,014.12	307,719,145.65	-9.72
Net profit attributable to owners of the parent company after deducting non-recurring profit or loss	254,128,319.48	274,208,661.74	-7.32
Basic earnings per share (RMB)	0.72	0.80	-10.00
Weighted average returns on net assets (%)	9.93	11.85	Decreased by 1.92 percentage points
Total assets	3,649,560,924.88	3,409,766,690.91	7.03
Owners' equity attributable to the parent company	2,877,466,853.34	2,719,699,779.72	5.80
Share capital	383,568,500.00	384,280,000.00	-0.19
Net assets per share attributable to owners of the parent company (RMB)	7.50	7.08	5.93

Notes: 1. The data as at the beginning of the reporting period is the same as the data statutorily disclosed as at the end of last year.

2. Unless otherwise stated, all values in this announcement are rounded to two decimal places, and any discrepancies are due to rounding.

3. The above financial data and indicators are based on the data from the consolidated financial statements but are not audited. The final results included in the 2023 annual report of the Company shall prevail.

II. EXPLANATION OF THE OPERATING RESULTS AND FINANCIAL POSITION

(1) Operating Conditions, Financial Position and Major Factors Affecting Operating Results during the Reporting Period

1. Operating Conditions

In 2023, the Company achieved a total operating revenue of RMB1,208,523,845.88, representing a year-on-year increase of 0.58%; operating profit of RMB305,975,463.53, representing a year-on-year decrease of 6.97%; gross profit of RMB305,905,863.04, representing a year-on-year decrease of 9.19%; net profit attributable to owners of the parent company of RMB277,824,014.12, representing a year-on-year decrease of 9.72%; net profit attributable to owners of the parent company after deducting non-recurring profit or loss of RMB254,128,319.48, representing a year on-year decrease of 7.32%; and basic earnings per share of RMB0.72, representing a year-on-year decrease of 10.00%.

2. Financial Position

At the end of the reporting period, the total assets of the Company amounted to RMB3,649,560,924.88, representing an increase of 7.03% as compared to the beginning of the period. Owners' equity attributable to the parent company amounted to RMB2,877,466,853.34, representing an increase of 5.80% as compared to the beginning of the period. Net assets per share attributable to owners of the parent company amounted to RMB7.50, representing an increase of 5.93% as compared to the beginning of the period.

3. Major Factors Affecting Operating Results

In 2023, owing to the implementation of the PRC's bulk purchase of high-value consumables, the terminal price of related products of the Company decreased, resulting in a decrease in net profit of the Company.

In the future, the Company will continue its innovative research and development in the joints, spinal and sports medicine product lines, while further accelerating the progress of its strategic projects in the areas of new materials, dental, platelet-rich plasma (PRP) preparation systems and robot in order to maintain the advantages of the Company in innovation capability and product reserves. Meanwhile, the Company will strengthen its lean management, reduce costs and increase efficiency, and fully expand its market share so as to sustain the rapid growth of the Company.

(2) Description of Indicators with Change of 30% or More

NIL.

III. RISK WARNING

There are no material uncertainties in the Company that may affect the accuracy of the content of this announcement. The major financial data for the year 2023 contained in this announcement is preliminary accounting data and have not been audited by an accounting firm and is subject to the audited 2023 annual report of the Company to be duly disclosed. Investors are reminded of the investment risks.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Chairman
Shi Wenling

Beijing, the PRC, 28 February 2024

As at the date of this announcement, the executive Directors of the Company are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Ms. Yao Lijie, Mr. Wong Tak Shing and Mr. Weng Jie.

* *For identification purposes only*